{"id":"nct:NCT07716098","kind":"trial","title":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","authors":["Janssen Research & Development, LLC"],"author_count":1,"year":2026,"published":"2026-07-21","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07716098","source_url":"https://clinicaltrials.gov/study/NCT07716098","archive_url":"https://space-kitty.com/papers/nct:NCT07716098","updated":"2026-09-25","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \\[mg\\] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \\[MDD\\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Depressive Disorder, Treatment-Resistant"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":348,"sponsor":"Janssen Research & Development, LLC","conditions":["Depressive Disorder, Treatment-Resistant"],"interventions":["DRUG: Esketamine 56 mg","DRUG: Esketamine 84 mg","DRUG: Placebo"],"start_date":"2026-07-23","start_date_type":"ACTUAL","primary_completion_date":"2028-12-27","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}